ClinicalTrials.gg
CompletedNCT01734772Updated May 5, 2014Results posted

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

A Phase 1 interventional study of dabigatran etexilate and dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran exposure (in Part II)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects.

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Reference (Part 1/A, Part 2/C)

    multiple doses of dabigatran (alone)

    Drug: dabigatran etexilate

  • Experimental
    Test 1 (Part 1/Treatment B)

    concomitant administration of dabigatran and ticagrelor

    Drug: dabigatran etexilate · Drug: ticagrelor

  • Experimental
    Test 2 (Part 2/Treatment D)

    staggered administration of ticagrelor and dabigatran

    Drug: ticagrelor · Drug: dabigatran etexilate

Interventions

  • Drugdabigatran etexilate

    multiple doses of dabigatran

  • Drugdabigatran etexilate

    medium dose dabigatran

  • loading dose of ticagrelor

  • multiple doses of ticagrelor

  • loading dose of ticagrelor

  • Drugdabigatran etexilate

    single dose of dabigatran

06

What researchers measure

Primary outcomes

  1. Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

    Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss).

    Time frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours

  2. Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)

    Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).

    Time frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours

07

Results

Posted May 5, 2014

Participant flow

Participant flow — Overall Study
MilestonePart 1Part 2
Started2424
Completed2321
Not completed13
Withdrew: Adverse event12
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryTotal Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)

Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss).

Time frame:
47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours
Reported as:
Geometric mean · ng*h/mL
Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
ng*h/mLDabigratan Etexilate 110mg Bid Alone - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1Dabigratan Etexilate 110mg Bid Alone - Part 2Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2
Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)551 ± 59.0817 ± 43.3689 ± 55.1660 ± 39.6844 ± 43.4
Statistical analysis
  • Dabigratan Etexilate 110mg Bid Alone - Part 1 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 · ANOVA · p = 0.9456 (p-value for ratio outside interval 80% - 125%) · Geometric mean ratio: 149.38 · 90% CI 124.388 to 179.383The dispersion value is actually the intraindividual gCV.
  • Dabigratan Etexilate 110mg Bid Alone - Part 1 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 · ANOVA · p = 0.5481 (p-value for ratio outside interval 80% - 125%) · Geometric mean ratio: 126.47 · 90% CI 107.363 to 148.967The dispersion value is actually the intraindividual gCV.
  • Dabigratan Etexilate 110mg Bid Alone - Part 2 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 · ANOVA · p = 0.5665 (p-value for ratio outside interval 80% - 125%) · Geometric mean ratio: 127.01 · 90% CI 108.047 to 149.295The dispersion value is actually the intraindividual gCV.
PrimaryTotal Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)

Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).

Time frame:
47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours
Reported as:
Geometric mean · ng/mL
Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)
ng/mLDabigratan Etexilate 110mg Bid Alone - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1Dabigratan Etexilate 110mg Bid Alone - Part 2Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2
Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)83.6 ± 69.3136 ± 45.4106 ± 65.197.6 ± 46.5121 ± 45.2
Statistical analysis
  • Dabigratan Etexilate 110mg Bid Alone - Part 1 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1 · ANOVA · p = 0.9841 (p-value for ratio outside interval 80% - 125%) · Geometric mean ratio: 164.74 · 90% CI 133.945 to 202.619The dispersion value is actually the intraindividual gCV.
  • Dabigratan Etexilate 110mg Bid Alone - Part 1 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1 · ANOVA · p = 0.6003 (p-value for ratio outside interval 80% - 125%) · Geometric mean ratio: 128.61 · 90% CI 106.370 to 155.495The dispersion value is actually the intraindividual gCV.
  • Dabigratan Etexilate 110mg Bid Alone - Part 2 vs Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2 · ANOVA · p = 0.4656 (p-value for ratio outside interval 80% - 125%) · Gmean ratio: 123.82 · 90% CI 102.695 to 149.288The dispersion value is actually the intraindividual gCV.

Adverse events

Collected over 11 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigratan Etexilate 110mg Bid Alone - Part 1—0/24 (0%)0/24 (0%)
Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1—0/23 (0%)0/23 (0%)
Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1—0/23 (0%)0/23 (0%)
Dabigratan Etexilate 110mg Bid Alone - Part 2—0/24 (0%)2/24 (8.3%)
Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2—0/21 (0%)0/21 (0%)
Most frequent other events
Most frequent other events
EventDabigratan Etexilate 110mg Bid Alone - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 1Dabigatran Etexilate 110mg Bid + Ticagrelor 90mg Bid - Part 1Dabigratan Etexilate 110mg Bid Alone - Part 2Dabigatran Etexilate 110mg Bid + Ticagrelor 180 mg - Part 2
HeadacheNervous system disorders0/240/230/232/240/21

Baseline characteristics

Treated Set which includes all subjects who were documented to have received at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(years)Part 1Part 2Total
Mean28.0 ± 7.228.6 ± 7.128.3 ± 7.15
Sex: Female, Male
Sex: Female, Male(Participants)Part 1Part 2Total
Female000
Male242448
08

Study locations

1 site
  • 1160.142.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2012
First posted
Nov 28, 2012
Start
Nov 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
May 5, 2014
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01734772
Responsible party
Sponsor
First posted
Nov 28, 2012
Start date
Nov 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
May 5, 2014
Last update
May 5, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion